SL32113: Specialised integrated unit 6: oncology and palliative care
[Page last updated: 26 October 2023]
| Academic Year: | 2023/24 |
| Owning Department/School: | Department of Life Sciences |
| Credits: | 10 [equivalent to 20 CATS credits] |
| Notional Study Hours: | 200 |
| Level: | Honours (FHEQ level 6) |
| Period: |
|
| Assessment Summary: | CWSI 50%, EXCB 50% |
| Assessment Detail: |
|
| Supplementary Assessment: |
|
| Requisites: | |
| Learning Outcomes: |
By the end of the unit, you will be able to:
1. Discuss the aetiology, epidemiology, pathophysiology and clinical symptoms of common cancers and how they are prevented, diagnosed and treated.
2. Demonstrate an in-depth knowledge and understanding of the disease process in cancer and the complexity of its treatment.
3. Explain the disease and patient monitoring factors in malignant diseases.
4. Identify and critically evaluate evidence-based approaches for the management of common malignancies and those receiving palliative care.
5. Explain formulation, pharmacokinetic and pharmacogenetic approaches as tools to optimize therapy outcomes for patients with cancer and receiving palliative care.
6. Explain the principles and concepts in providing palliative care to patients with malignant and non-malignant disease.
7. Describe the primary and secondary care roles for healthcare professionals/pharmacists in the treatment of cancer and in palliative care.
8. Make appropriate clinical decisions in support of rational treatment of patients with cancer and those receiving palliative care.
9. Apply complex structured consultation skills to the conditions studied during this unit. |
| Synopsis: | This unit will provide you with a comprehensive, integrated understanding of the design and development of medicines, their pharmacological actions in the body and the evidence-based approach to treatment of patients with the aim of promoting safe and effective outcomes in oncology and palliative care. |
| Content: | Clinical introduction and overview of therapeutic area
Cancer prevention, screening programmes and early diagnosis including the role of the pharmacist
Molecular biology of cancer, oncogenes, tumour suppressors, angiogenesis, metastases
Basics of chemotherapy, dose approaches in cancer, drug delivery
Advanced applications of molecular modelling
Drug design - Hormonal regulation, anti-metabolites, mitotic spindles, alkylators, DNA cleavers, intercalators, biological targeting, cell cycle regulators
The medicinal chemistry of anti-oestrogens and anti - androgens
Individualized therapy in oncology and palliative care: pharmacogenomics and pharmacogenetic approaches, ADME, dose individualization in cancer patients and precision medicine
Use of immunotherapy in cancer: design, formulation and clinical use (including monoclonal antibodies, checkpoint inhibitors and vaccines)
Passive and active targeted drug delivery
Advanced therapy medicinal products including cell-based therapies, gene therapy. Stem cells and regenerative medicine
Diagnostic genotyping
Diagnostics and Imaging - Contrast media
Clinical treatment of common cancers including radiotherapy and surgery as treatment options.
Radiation - decay and theory, use in imaging, radiotherapy, radiopharmaceuticals
Complications with chemotherapy
Supportive treatments - anti-emetics, GCSF, prophylaxis antibiotics
Principles of clinical decision making in oncology
Pharmacoeconomic issues in oncology
Current research in cancer to include skin cancer, UV therapies and prostate cancer research
Palliative care services in the UK
Symptom control in malignant and non-malignant disease
Continuous SC Infusion Devices and reference sources
Care at the end of life
Simulation and practice-based learning in oncology and palliative care |
| Course availability: |
SL32113 is a Must Pass Unit on the following courses:Department of Life Sciences
|
Notes:
|